Mizuho raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $24 from $23 and keeps a Neutral rating on the shares following the “good” Q2 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion
- Acadia Pharmaceuticals price target raised to $27 from $23 at BofA
- Acadia Pharmaceuticals price target raised to $38 from $37 at Citizens JMP
- ACADIA Pharmaceuticals: Strong Financial Performance and Promising Outlook Justify Buy Rating
- ACADIA Pharmaceuticals: Balanced Outlook Amid Solid Performance and Future Uncertainties